اثر سيتي كولين در بيماران سكته مغزي

Efficacy Citicoline in Stroke Patients

Citicoline (CDP-Choline) is an essential intermediate in the biosynthetic pathway of Phosphatidylcholine, and the later is a main component of neuronal membranes. Many experimental and few clinical studies showed the beneficial effect of citicoline in cerebro-vascular diseases, memory disturbances and cognitive disorders. The current trial was a case - control study in 60 (40 patients as the cases and 20 patients as controls) nondiabetic, 50-70 years old patients who had an ischemic stroke in the MCA territory for the first time. Citicoline (500 mg/day/IV or IM) was administered in the first 24h of stroke and continued for 4 weeks. Barthel Index measured the neurologic function of the patients in the first day, 4th week and eighth week. After 4 weeks patients in citicoline group had significantly greater improvement of neurologic function (p=0/01). Patients with more severe disability (Bl< 45) had more improvement at the end of 4th and 8th week. (59,5 for citicoline and 39,6 for control group (p=0.001). The percent of patients who had a full recovery (95) were greatly higher in citicoline group at eighth week. This study suggest that citicoline was effective in enhancing neuroligic recovery in stroke patients especially in a subgroup of patients who had more disability at the beginning.